Download Files:

Brimonidine (tartrate)

$50$150

Products Details

Product Description

– Brimonidine tartrate (UK 14304 tartrate) is a full α2-adrenergic receptor (α2-AR) agonist.

Web ID

– HY-B0659A

Storage Temperature

– 4°C (Powder, sealed storage, away from moisture)

Shipping

– Room Temperature

Molecular Formula

– C15H16BrN5O6

References

– [1]Andorn, A.C., M.A. Carlson, and R.C. Gilkeson, Specific [3H]UK 14,304 binding in human cortex occurs at multiple high affinity states with alpha 2-adrenergic selectivity and differing affinities for GTP. Life Sci, 1988. 43(22): p. 1805-12.|[2]Cambridge, D., UK-14,304, a potent and selective alpha2-agonist for the characterisation of alpha-adrenoceptor subtypes. Eur J Pharmacol, 1981. 72(4): p. 413-5.|[3]Chopin, P., F.C. Colpaert, and M. Marien, Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J Pharmacol Exp Ther, 1999. 288(2): p. 798-804.

CAS Number

– 70359-46-5

Molecular Weight

– 442.22

Compound Purity

– 99.14

SMILES

– O=C(O)[C@H](O)[C@@H](O)C(O)=O.BrC1=C2N=CC=NC2=CC=C1NC3=NCCN3

Clinical Information

– Launched

Research Area

– Endocrinology; Cancer

Solubility

– DMSO : 50 mg/mL (ultrasonic)|H2O : 25 mg/mL (ultrasonic)

Target

– Adrenergic Receptor

Isoform

– α adrenergic receptor

Pathway

– GPCR/G Protein;Neuronal Signaling

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.